Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study
The aim of this study was to analyze the therapeutic results and survival of patients with myelofibrosis treated with ruxolitinib in comparison with a group on standard therapy. It is a cross-sectional, retrospective, non-interventional, real-life study that was performed between January 2000 and Fe...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/20/5085 |
| _version_ | 1797574312703557632 |
|---|---|
| author | Vera Stoeva Georgi Mihaylov Konstantin Mitov Guenka Petrova Konstantin Tachkov |
| author_facet | Vera Stoeva Georgi Mihaylov Konstantin Mitov Guenka Petrova Konstantin Tachkov |
| author_sort | Vera Stoeva |
| collection | DOAJ |
| description | The aim of this study was to analyze the therapeutic results and survival of patients with myelofibrosis treated with ruxolitinib in comparison with a group on standard therapy. It is a cross-sectional, retrospective, non-interventional, real-life study that was performed between January 2000 and February 2023. Patients treated between 2000 and 2016, before the introduction of ruxolitinib, constituted the control group (<i>n</i> = 45), while those treated after May 2016, after ruxolitinib inclusion, constituted the active group (<i>n</i> = 66). Demographic characteristics, clinical indicators, the severity of the disease, and survival were explored using Kaplan–Meier survival analyses. Spearman’s correlation, linear regression, and other statistical analyses were performed. According to the Kaplan–Meier analysis, there was a 75.33% reduction in the fatality risk in the sample. On a general-population level, the fatality risk in the group treated with ruxolitinib varied between 7.9% and 77.18% compared to that of the risk in the control group. There was a decrease in blood parameters (leukocytes, hemoglobin, and platelets) and spleen size. During the first six months, the spleen size of the patients on ruxolitinib decreased by 6%, and during the second six months, it decreased by another 9%. This study shows that patients in a real-life clinical setting treated with ruxolitinib exhibited improved clinical signs of the disease, had a lower symptom severity, and survived longer than patients on standard therapy before ruxolitinib’s entrance into the national market. The improvements correlate with those reported in randomized clinical trials. |
| first_indexed | 2024-03-10T21:21:13Z |
| format | Article |
| id | doaj.art-04c699093219410086c391b010d4fd50 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T21:21:13Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-04c699093219410086c391b010d4fd502023-11-19T16:00:22ZengMDPI AGCancers2072-66942023-10-011520508510.3390/cancers15205085Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal StudyVera Stoeva0Georgi Mihaylov1Konstantin Mitov2Guenka Petrova3Konstantin Tachkov4Specialized Hospital for Active Treatment of Hematological Diseases, 1000 Sofia, BulgariaSpecialized Hospital for Active Treatment of Hematological Diseases, 1000 Sofia, BulgariaFaculty of Pharmacy, Medical University of Sofia, 1000 Sofia, BulgariaFaculty of Pharmacy, Medical University of Sofia, 1000 Sofia, BulgariaFaculty of Pharmacy, Medical University of Sofia, 1000 Sofia, BulgariaThe aim of this study was to analyze the therapeutic results and survival of patients with myelofibrosis treated with ruxolitinib in comparison with a group on standard therapy. It is a cross-sectional, retrospective, non-interventional, real-life study that was performed between January 2000 and February 2023. Patients treated between 2000 and 2016, before the introduction of ruxolitinib, constituted the control group (<i>n</i> = 45), while those treated after May 2016, after ruxolitinib inclusion, constituted the active group (<i>n</i> = 66). Demographic characteristics, clinical indicators, the severity of the disease, and survival were explored using Kaplan–Meier survival analyses. Spearman’s correlation, linear regression, and other statistical analyses were performed. According to the Kaplan–Meier analysis, there was a 75.33% reduction in the fatality risk in the sample. On a general-population level, the fatality risk in the group treated with ruxolitinib varied between 7.9% and 77.18% compared to that of the risk in the control group. There was a decrease in blood parameters (leukocytes, hemoglobin, and platelets) and spleen size. During the first six months, the spleen size of the patients on ruxolitinib decreased by 6%, and during the second six months, it decreased by another 9%. This study shows that patients in a real-life clinical setting treated with ruxolitinib exhibited improved clinical signs of the disease, had a lower symptom severity, and survived longer than patients on standard therapy before ruxolitinib’s entrance into the national market. The improvements correlate with those reported in randomized clinical trials.https://www.mdpi.com/2072-6694/15/20/5085myelofibrosisruxolitinibtherapeutic resultssurvival analysis |
| spellingShingle | Vera Stoeva Georgi Mihaylov Konstantin Mitov Guenka Petrova Konstantin Tachkov Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study Cancers myelofibrosis ruxolitinib therapeutic results survival analysis |
| title | Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study |
| title_full | Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study |
| title_fullStr | Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study |
| title_full_unstemmed | Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study |
| title_short | Therapeutic Results and Survival of Patients with Myelofibrosis Treated with Ruxolitinib—A Real-Life Longitudinal Study |
| title_sort | therapeutic results and survival of patients with myelofibrosis treated with ruxolitinib a real life longitudinal study |
| topic | myelofibrosis ruxolitinib therapeutic results survival analysis |
| url | https://www.mdpi.com/2072-6694/15/20/5085 |
| work_keys_str_mv | AT verastoeva therapeuticresultsandsurvivalofpatientswithmyelofibrosistreatedwithruxolitinibareallifelongitudinalstudy AT georgimihaylov therapeuticresultsandsurvivalofpatientswithmyelofibrosistreatedwithruxolitinibareallifelongitudinalstudy AT konstantinmitov therapeuticresultsandsurvivalofpatientswithmyelofibrosistreatedwithruxolitinibareallifelongitudinalstudy AT guenkapetrova therapeuticresultsandsurvivalofpatientswithmyelofibrosistreatedwithruxolitinibareallifelongitudinalstudy AT konstantintachkov therapeuticresultsandsurvivalofpatientswithmyelofibrosistreatedwithruxolitinibareallifelongitudinalstudy |